Copy to clipboard 
CONMED reported 4Q24 orthopedic sales of $139 million, up 1.8% compared to the fourth quarter of 2023. For the full year, the company generated $543.9 million in orthopedic sales, up 2% compared to the prior year.
The company’s longstanding supply chain issues kept it from growing in line with the market, especially in sports medicine. However, CONMED’s foot and ankle business attained better performance in the fourth quarter.
“We made progress on our supply challenges throughout 2024, but not as quickly as we had planned,” said CONMED CEO Pat Beyer. “Our sales force is now back on offense in Foot & Ankle, while there is still work ongoing in other areas of Orthopedic. To that end, we recently engaged a top-tier consulting firm that is helping us drive change more rapidly and turn our operations from an area of weakness into an area of strength.”
There is significant uncertainty around tariffs. CONMED could face up to $45 million in extra import costs for Canada and Mexico combined. Expiring exemptions in China could mean $10.5 million in additional annual costs starting in June.
Given the uncertainty, the company is excluding tariff impacts on its 2025 guidance. CONMED expects total sales growth between 4% and 6% on a constant currency basis.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $13.3 | $12.3 | $1.0 | 8.0% |
| Sports Medicine | $125.7 | $124.2 | $1.5 | 1.2% |
| Total | $139.0 | $136.5 | $2.5 | 1.8% |
| Segment | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $48.0 | $46.5 | $1.5 | 3.1% |
| Sports Medicine | $496.0 | $486.7 | $9.3 | 1.9% |
| Total | $543.9 | $533.2 | $10.8 | 2.0% |
Orthopedic Sales by Geography
| Region | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $54.7 | $52.0 | $2.7 | 5.2% |
| OUS | $84.3 | $84.5 | -$0.2 | -0.3% |
| EMEA | $34.1 | $32.5 | $1.6 | 5.0 |
| APAC | $27.4 | $30.0 | -$2.6 | -8.7% |
| ROW | $22.7 | $22.0 | $0.7 | 3.4% |
| Total | $139.0 | $136.5 | $2.5 | 1.8% |
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $210.7 | $199.5 | $11.2 | 5.6% |
| OUS | $333.3 | $333.6 | -$0.4 | -0.1% |
| EMEA | $131.1 | $128.9 | $2.3 | 1.8% |
| APAC | $117.7 | $121.0 | -$3.3 | -2.8% |
| ROW | $84.5 | $83.7 | $0.7 | 0.8% |
| Total | $534.9 | $533.1 | $10.8 | 2.0% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,307 | |
| Cost of Sales | $574.0 | 43.9% |
| Selling and Admin | $478.3 | 36.6% |
| R & D | $54.4 | 4.2% |
| Other | $67.9 | 5.2% |
| Net Earnings | $132.4 | 10.1% |
CONMED reported 4Q24 orthopedic sales of $139 million, up 1.8% compared to the fourth quarter of 2023. For the full year, the company generated $543.9 million in orthopedic sales, up 2% compared to the prior year.
The company's longstanding supply chain issues kept it from growing in line with the market, especially in sports medicine....
CONMED reported 4Q24 orthopedic sales of $139 million, up 1.8% compared to the fourth quarter of 2023. For the full year, the company generated $543.9 million in orthopedic sales, up 2% compared to the prior year.
The company’s longstanding supply chain issues kept it from growing in line with the market, especially in sports medicine. However, CONMED’s foot and ankle business attained better performance in the fourth quarter.
“We made progress on our supply challenges throughout 2024, but not as quickly as we had planned,” said CONMED CEO Pat Beyer. “Our sales force is now back on offense in Foot & Ankle, while there is still work ongoing in other areas of Orthopedic. To that end, we recently engaged a top-tier consulting firm that is helping us drive change more rapidly and turn our operations from an area of weakness into an area of strength.”
There is significant uncertainty around tariffs. CONMED could face up to $45 million in extra import costs for Canada and Mexico combined. Expiring exemptions in China could mean $10.5 million in additional annual costs starting in June.
Given the uncertainty, the company is excluding tariff impacts on its 2025 guidance. CONMED expects total sales growth between 4% and 6% on a constant currency basis.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $13.3 | $12.3 | $1.0 | 8.0% |
| Sports Medicine | $125.7 | $124.2 | $1.5 | 1.2% |
| Total | $139.0 | $136.5 | $2.5 | 1.8% |
| Segment | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $48.0 | $46.5 | $1.5 | 3.1% |
| Sports Medicine | $496.0 | $486.7 | $9.3 | 1.9% |
| Total | $543.9 | $533.2 | $10.8 | 2.0% |
Orthopedic Sales by Geography
| Region | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $54.7 | $52.0 | $2.7 | 5.2% |
| OUS | $84.3 | $84.5 | -$0.2 | -0.3% |
| EMEA | $34.1 | $32.5 | $1.6 | 5.0 |
| APAC | $27.4 | $30.0 | -$2.6 | -8.7% |
| ROW | $22.7 | $22.0 | $0.7 | 3.4% |
| Total | $139.0 | $136.5 | $2.5 | 1.8% |
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $210.7 | $199.5 | $11.2 | 5.6% |
| OUS | $333.3 | $333.6 | -$0.4 | -0.1% |
| EMEA | $131.1 | $128.9 | $2.3 | 1.8% |
| APAC | $117.7 | $121.0 | -$3.3 | -2.8% |
| ROW | $84.5 | $83.7 | $0.7 | 0.8% |
| Total | $534.9 | $533.1 | $10.8 | 2.0% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $1,307 | |
| Cost of Sales | $574.0 | 43.9% |
| Selling and Admin | $478.3 | 36.6% |
| R & D | $54.4 | 4.2% |
| Other | $67.9 | 5.2% |
| Net Earnings | $132.4 | 10.1% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
